Biomarkers in geriatric psychiatry: searching for the holy grail?
Biomarkers in geriatric psychiatry: searching for the holy grail?
复制标题
DOI：
10.1097/yco.0b013e328314b763
复制
发表时间：
2008-11-01
影响因子：
6.9
通讯作者：
Mulsant, Benoit H.
中科院分区：
文献类型：
--
作者：
Blumberger, Daniel M.;Daskalakis, Zafiris J.;Mulsant, Benoit H.
Purpose of reviewBiomarkers in clinical medicine are used to detector diagnose specific illnesses, predict disease progression, and predict the response to treatment. As the proportion of adults over 65 years of age rises, there is a growing need to detect neurodegenerative disease at an earlier stage with the goal of improving treatment for highly prevalent illnesses such as late-life depression and dementia.Recent findingsThe search for biomarkers of late-life mental disorders includes the exploration of structural neuroimaging, functional neuroimaging, genomics, proteomics, noninvasive neurophysiology, cerebrospinal fluid, and plasma analysis. Novel structural and functional neuroimaging techniques that have recently been developed show promise as biomarkers of both late-life depression and specific dementia syndromes. The fields of proteomics and genomics are advancing our ability to identify genes and aberrant proteins that detect preclinical dementia. As depression is often a harbinger of dementia in late life, recent studies are beginning to elucidate the relationship between different types of late-life depression and the subsequent emergence of dementia.SummaryBiomarker research in late-life mental disorders is progressing at a rapid pace. The application of current biomarkers to clinical practice may be on the horizon with further research that refines their sensitivity and specificity.
